Cell Therapy a Focus at BIO-Europe® in Munich

October 23, 2015 Erin Righetti

fobpReprinted in part from Future of BioPharma blog post 10/20/2015

 

On November 2, Michel Detheux, CEO of iTeos Therapeutics, returns as a panelist for BIO-Europe® 2015 in Munich. On that day, BIO-Europe will partner with the Alliance for Regenerative Medicine (ARM) to showcase some of the biggest movers and shakers in the cell therapy and regenerative medicine space. For a preview, you can watch Detheux at BIO-Europe 2014 on a panel with others from Novartis, Innovio and Bristol-Myers Squibb here. Their discussion focused on answering questions such as: “Are there opportunities to remain a company without having to exit?” and  “Is it the endgame to get acquired?”

Is it the endgame to get acquired? – At the event last year, Detheux answered this question by commenting that his company would be running out of funds the following year and that: “If a company like iTeos wants to get access to a large portfolio of different immunotherapies we need to partner quite early stage.”

 

Partnership with Pfizer – In December 2014, iTeos partnered with Pfizer. iTeos gave Pfizer rights to their pre-clinical compounds targeting ID01 and TD02 while Pfizer was to be responsible for the development and commercialization of ID01 and TD02 drug candidates.

 

Read the entire post on Future of BioPharma.
Coverage of BIO-Europe 2015 panels and workshops will be posted here and will also be available online soon.

Read more...

Previous Article
The earlier you establish a presence, the greater the reward: Biolatam®
The earlier you establish a presence, the greater the reward: Biolatam®

The Latin America healthcare market continues to grow, and governments are continuing to allocate spending ...

Next Article
MC Services supports joint initiative with BioM and EBD Group at BIO-Europe to introduce young journalists to the biosciences
MC Services supports joint initiative with BioM and EBD Group at BIO-Europe to introduce young journalists to the biosciences

In a press release today, MC Services AG, the international Investor Relations and Public Relations firm, a...